• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

UPDATE: Legislation Promising Quicker FDA Approval of Animal Drugs Signed By President

August 21, 2018
American Veterinarian Staff

President Trump recently signed a bill that would give veterinarians more access to FDA-approved drugs.

UPDATE (August 21) — Last week, President Trump signed the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 into law. These amendments will require drug makers to submit applications electronically starting October 1. The legislation charges fees for drug and device applications and then uses that money to speed up their review so the products can head to market faster. The 2 measures are part of the Food, Drug, and Cosmetic Act and are directed at both generic and brand-name drugs.

The bill must be re-authorized every 5 years.

Advertisement

In what is considered a significant victory for the veterinary industry, both the House and Senate have passed a bill that will grant veterinarians more access to FDA-approved drugs. Currently, there are about 25 times more labeled indications approved for human use than for animal use.

“These programs are critically important when it comes to the care of our pets and the farmers that help produce the food that feeds our country,” Rep. Greg Walden, chairman of the Energy and Commerce Committee, and Rep. Michael C. Burgess, MD, chairman of Subcommittee on Health, said in a joint statement. “We applaud the Senate’s swift passage of this important reauthorization and look forward to President Trump soon signing into law.”

RELATED:

  • Pfizer Suspends Delivery of Injectable Opioids to Veterinary Customers
  • FDA Approves Chewable Form of Dog, Cat Antibiotic

If it is signed into law, the Animal Drug User Fee Amendments (ADUFA) and Animal Generic Drug User Fee Amendments (AGDUFA) of 2018 (H.R. 5554/S.2434) will reauthorize the FDA’s Center for Veterinary Medicine to continue collecting animal drug and animal generic drug user fees from the drugs’ sponsors. These fees support the FDA’s animal drug review procedures and speed up the process of gaining veterinary access to FDA-approved drugs.

The American Veterinary Medical Association (AVMA) has been vocal about its support for the passing of the bill. In March, Michael Topper, DVM, PhD, DACVP, AVMA’s immediate past president, testified before the US House of Representatives in favor of the legislation.

"By providing new animal drugs with a predictable pathway to market, these fees help provide veterinarians with access to new and additional tools that can potentially improve treatment outcomes, provide alternatives to existing therapies, fill unmet medical needs in veterinary medicine, and ultimately improve patient care, which is the center of veterinary practice," Dr. Topper said.


Advertisement

Latest News

The four-letter word to why you're burning out and feeling unproductive

Merck Manuals recognizes importance of One Health concept

Topical therapy and immunotherapy can save time and frustration with dermatology cases

Texas Tech appoints new faculty member with passion for animal agriculture

View More Latest News
Advertisement